To include your compound in the COVID-19 Resource Center, submit it here.

SCM raises $35M series C for stem cells to treat inflammation

SCM Lifescience (Incheon, South Korea) closed a $35 million series C round from 15 investors last Friday to advance its pipeline of disease-specific

Read the full 233 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE